Revolutionizing the Treatment of Inflammatory Skin Conditions

Opzelura (ruxolitinib). Are you or someone you know struggling with inflammatory skin conditions such as atopic dermatitis or psoriasis? Have traditional treatments failed to provide relief? If so, you may be interested in learning more about Opzelura (ruxolitinib), a novel treatment that is changing the game for patients with chronic skin conditions.

What is Opzelura (ruxolitinib)

Opzelura is a topical Janus kinase (JAK) inhibitor that works by targeting the underlying cause of inflammatory skin conditions. Unlike traditional treatments such as corticosteroids or immunosuppressants, Opzelura specifically blocks the JAK pathway, which plays a key role in the inflammation process. This targeted approach not only provides relief from symptoms such as itching and redness but also helps to reduce the overall inflammation in the skin.

Opzelura (ruxolitinib) is a Janus kinase (JAK) inhibitor.

It’s used for short-term treatment of:

• Mild to moderate eczema (atopic dermatitis) in non-immunocompromised people over 12. It’s for those who can’t use topical treatments.

It’s also approved for treating:

• Non-segmental vitiligo in patients aged 12 and up.

How does Opzelura (ruxolitinib) work?

Opzelura (ruxolitinib) blocks the Janus Kinase (JAK) enzymes. This includes JAK 1 and JAK 2. These enzymes play a role in how cells respond to cytokines, like interferon-gamma.

This can help the immune system cells that attack melanocytes. It lets them produce pigment again.

In vitiligo, Opzelura helps the skin regain color.

The JAK enzymes also affect skin inflammation, itching, and barrier function. By blocking these enzymes, Opzelura can reduce eczema symptoms. This includes itch, rash, and redness.

What are the benefits of Opzelura?

One of the main benefits of Opzelura is its targeted approach to treating inflammatory skin conditions. By specifically blocking the JAK pathway, Opzelura helps to address the root cause of the inflammation, rather than just treating the symptoms. This can lead to faster and more effective relief for patients, with fewer side effects compared to traditional treatments.
Additionally, Opzelura is a topical treatment, meaning it is applied directly to the skin where it is needed. This localized approach can help to minimize systemic side effects and reduce the risk of drug interactions, making it a safe and well-tolerated option for many patients.

Is Opzelura right for you?

If you have been struggling to find relief from your inflammatory skin condition, it may be worth talking to your healthcare provider about Opzelura. This innovative treatment has been shown to be effective in clinical trials and is now available for patients in need of a new solution. With its targeted approach and minimal side effects, Opzelura may be the answer you have been looking for.

Where has Opzelura (ruxolitinib) been approved?

Opzelura (ruxolitinib) has been approved in several places:

For treating moderate to severe eczema in patients aged 12 and up

• Approved by The Good and Drug Administration (FDA), USA on Sept 21, 2021.

For treating non-segmental vitiligo

• Approved by The Food and Drug Administration (FDA), USA on July 18, 2022.
• Approved by The European Medicines Agency (EMA) on Apr 19, 2023.

This medicine might be approved in other places too. If you have questions, contact our support team.

How is Opzelura (ruxolitinib) taken?

The usual way to take it is:

• Apply a thin layer of cream twice a day to affected skin areas.

For eczema patients: Apply Opzelura on up to 20% of your body. Use no more than one 60 g tube a week.

Stop using Opzelura when your eczema signs and symptoms go away. If it doesn’t improve in 8 weeks, talk to your doctor.

For vitiligo patients: Apply Opzelura on depigmented skin twice a day, up to 10% of the body at once.

It may take more than 24 weeks to see results. If you haven’t seen repigmentation in this time, talk to your doctor.

Don’t use Opzelura with other treatments like biologics or JAK inhibitors. Also, avoid potent immunosuppressants like azathioprine or cyclosporine.

For more details on dosage and use, see the official prescribing information in our references section.

Note: Always follow your doctor’s advice for the right dosage.

Are there any known adverse reactions or side effects of Opzelura (ruxolitinib)?

Common adverse reactions

The most common side effects (≥1% of patients) listed in the prescribing information include:

In eczema patients

• Swelling of nasal passages
• Diarrhea
• Bronchitis
• Ear infection
• Increased eosinophil counts
• Urticaria
• Folliculitis
• Tonsillitis
• Runny nose.

In vitiligo patients

• Acne on the treated skin area
• Skin irritation and itchiness
• Swelling of nasal passages
• Headaches
• Urinary tract infections
• Redness of the skin
• Fever.

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include:

• Serious infections
• Major adverse cardiovascular events
• Clotting (thrombosis)
• Cancer and immune system problems
• All-cause mortality for patients taking JAK inhibitors orally (by mouth).

Use in a specific population

Before using Opzelura (ruxolitinib), tell your treating doctor about all of your medical conditions, including if you:

• Have an infection
• Have or had tuberculosis (TB), or have been in close contact with someone who has TB
• Have had shingles (herpes zoster)
• Have or had hepatitis B or C
• Have had skin cancer in the past
• You are a current or past smoker
• Have or have had low white or red blood cell counts
• Have high levels of fat in your blood (high cholesterol or triglycerides)
• You are pregnant or planning to become pregnant. It is not known if this medicine will harm your unborn baby.

Please refer to the official prescribing information for a comprehensive list of side effects and adverse reactions.